IPO - Profile


We are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission at Rallybio is aligned with our expertise, and we believe we have assembled the best people, partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$13.00 6,200,000 Positive High 10.82%

Offering Team

  • Legal counsel
  • Ropes & Gray LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 22 Jul, 2021

Offer 29 Jul, 2021

Look Ahead

Lock Up Expiry Jan 29, 2022

IPO Terms

Offer Price $13.00
Offer Size 6M

Market Sentiments

Stock Price